Prentice Wealth Management LLC Acquires 1,481 Shares of Pfizer Inc. (NYSE:PFE)

Prentice Wealth Management LLC lifted its stake in Pfizer Inc. (NYSE:PFE) by 9.1% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 17,692 shares of the biopharmaceutical company’s stock after purchasing an additional 1,481 shares during the period. Prentice Wealth Management LLC’s holdings in Pfizer were worth $469,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of PFE. Charles Schwab Investment Management Inc. raised its stake in shares of Pfizer by 11.0% in the third quarter. Charles Schwab Investment Management Inc. now owns 130,143,942 shares of the biopharmaceutical company’s stock worth $3,766,366,000 after buying an additional 12,864,343 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in Pfizer by 22.4% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 38,068,879 shares of the biopharmaceutical company’s stock worth $1,101,713,000 after acquiring an additional 6,977,587 shares in the last quarter. International Assets Investment Management LLC bought a new stake in Pfizer during the 3rd quarter worth approximately $146,481,000. Van ECK Associates Corp lifted its holdings in Pfizer by 28.5% during the fourth quarter. Van ECK Associates Corp now owns 21,286,805 shares of the biopharmaceutical company’s stock valued at $564,739,000 after purchasing an additional 4,726,549 shares in the last quarter. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. boosted its position in shares of Pfizer by 164.2% in the third quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 7,316,405 shares of the biopharmaceutical company’s stock worth $211,737,000 after purchasing an additional 4,546,809 shares during the period. 68.36% of the stock is owned by institutional investors.

Pfizer Trading Up 1.6 %

Shares of PFE opened at $26.32 on Friday. The stock has a market capitalization of $149.14 billion, a PE ratio of 18.66, a P/E/G ratio of 0.64 and a beta of 0.64. The company’s fifty day moving average is $26.30 and its 200 day moving average is $27.42. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. Pfizer Inc. has a fifty-two week low of $24.48 and a fifty-two week high of $31.54.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, topping analysts’ consensus estimates of $0.48 by $0.15. The firm had revenue of $17.76 billion for the quarter, compared to the consensus estimate of $17.26 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The business’s quarterly revenue was up 24.7% on a year-over-year basis. During the same period in the previous year, the firm posted $0.10 EPS. Sell-side analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, January 24th will be given a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, January 24th. This is an increase from Pfizer’s previous quarterly dividend of $0.42. This represents a $1.72 dividend on an annualized basis and a yield of 6.54%. Pfizer’s dividend payout ratio is 121.99%.

Analyst Upgrades and Downgrades

Several analysts have recently commented on PFE shares. Truist Financial decreased their price objective on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a research report on Wednesday, December 18th. Citigroup lowered their price objective on Pfizer from $30.00 to $29.00 and set a “neutral” rating on the stock in a research report on Tuesday, January 28th. StockNews.com lowered Pfizer from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, November 20th. UBS Group decreased their target price on Pfizer from $31.00 to $29.00 and set a “neutral” rating on the stock in a research note on Wednesday, January 8th. Finally, Evercore ISI upgraded Pfizer to a “strong-buy” rating in a research note on Wednesday, October 30th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating, six have issued a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, Pfizer presently has an average rating of “Moderate Buy” and a consensus target price of $31.92.

Insider Activity

In related news, Director Ronald E. Blaylock bought 19,457 shares of the business’s stock in a transaction dated Thursday, February 13th. The shares were purchased at an average price of $25.65 per share, with a total value of $499,072.05. Following the transaction, the director now owns 27,707 shares in the company, valued at $710,684.55. This trade represents a 235.84 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 0.06% of the company’s stock.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.